A Novel Paclitaxel Microemulsion Containing a Reduced Amount of Cremophor EL: Pharmacokinetics, Biodistribution, and In Vivo  Antitumor Efficacy and Safety by Wang, Ying et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 854872, 10 pages
doi:10.1155/2011/854872
Research Article
ANovel Paclitaxel MicroemulsionContainingaReduced
Amount of Cremophor EL: Pharmacokinetics, Biodistribution,
andInVivo Antitumor EfﬁcacyandSafety
YingWang,1,2 Ke-Chun Wu,1 Bing-Xiang Zhao,1 Xin Zhao,1 Xin Wang,1 Su Chen,1
Shu-FangNie,2 Wei-San Pan,2 XuanZhang,1 andQiang Zhang1,3
1Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
2Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road,
Shenyang 110016, China
3State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
Correspondence should be addressed to Xuan Zhang, xuanzhang18@163.com
Received 2 August 2010; Revised 23 October 2010; Accepted 16 December 2010
Academic Editor: Mark J. McKeage
Copyright © 2011 Ying Wang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The purpose of this study was to prepare a novel paclitaxel (PTX) microemulsion containing a reduced amount of Cremophor EL
(CrEL)whichhadsimilarpharmacokineticsandantitumoreﬃcacy asthecommercially available PTXinjection,butasigniﬁcantly
reduced allergic eﬀect due to the CrEL. The pharmacokinetics, biodistribution, in vivo antitumor activity and safety of PTX
microemulsion was evaluated. The results of pharmacokinetic and distribution properties of PTX in the microemulsion were
similar to those of the PTX injection. The antitumor eﬃcacy of the PTX microemulsion in OVCRA-3 and A 549 tumor-bearing
animals was similar to that of PTX injection. The PTX microemulsion did not cause haemolysis, erythrocyte agglutination or
simulative reaction. The incidence and degree of allergic reactions exhibited by the PTX microemulsion group, with or without
premedication, were signiﬁcantly lower than those in the PTX injection group (P<. 01). In conclusion, the PTX microemulsion
had similar pharmacokinetics and anti-tumor eﬃcacy to the PTX injection, but a signiﬁcantly reduced allergic eﬀect due to CrEL,
indicating that the PTX microemulsion overcomes the disadvantages of the conventional PTX injection and is one way of avoiding
the limitations of current injection product while providing suitable therapeutic eﬃcacy.
1.Introduction
Paclitaxel (PTX) is one of the most important compounds
which has recently been obtained from a natural source [1].
It is approved for the treatment of ovarian, breast, nonsmall
cell lung carcinomas and AIDS-related Kaposi’s sarcoma.
The currently available pharmaceutical formulation of PTX
(such as Taxol, Bristol-Myers Squibb, New York, NY, USA)
contains 30mg PTX dissolved in 5mL 50% Cremophor
EL (polyethoxylated castor oil, CrEL) and 50% dehydrated
ethanol (1:1, v/v) to enhance the solubility of PTX in
water. However, a large number of studies have reported
various side eﬀects of CrEL, such as hypersensitivity, neuro-
toxicity, and neuropathy [2, 3]. Therefore, premedication is
mandatory before paclitaxel administration. The premedica-
tion schedule includes corticosteroids, diphenhydramine or
chlorpheniramine, H2-receptor antagonists and antiemetics.
Despite such premedication, minor reactions (ﬂushing and
rash) still occur in 41–44% of all patients and major, poten-
tially life threatening, reactions in 1.5–3% [4–6]. Although
CrEL has been used to administer other drugs, such as
cyclosporine and teniposide, the amount of CrEL necessary
to deliver the required doses of Taxol is signiﬁcantly higher
than that used with any other commercially available drugs
[2].
Therefore, current approaches to improve this situation
are focused mainly on the development of formulations
that contain no CrEL. These strategies include increasing
the aqueous solubility of PTX by cosolvency, emulsiﬁcation,
microemulsiﬁcation, drug complexation with cyclodextrins,
carrier mediation using liposomes, nanoparticles, and struc-
tural modiﬁcation to obtain analogues and prodrugs [7].2 Journal of Biomedicine and Biotechnology
It has been reported that some CrEL-free or reduced
CrEL PTX formulations, such as Genexol-PM, AI-850, or
Genetaxyl, have been developed and evaluated in clinical tri-
als [8–11]. Now, a novel CrEL-free albumin-bound nanopar-
ticleformulationofPTX(ABI-007)hasbeenapprovedbythe
US Food and Drug Administration for pretreated metastatic
breast cancer patients. This formulation is prepared by high-
pressure homogenization of PTX in the presence of serum
albumin, resulting in a nanoparticle colloidal suspension.
The albumin concentration is 3-4%, which is similar to the
albumin concentration in blood [12].
Microemulsions are isotropic, thermodynamically stable
transparent (or translucent) systems of oil, water, and sur-
factant, frequently in combination with a cosurfactant with a
droplet size usually in the range of 20–200nm [13, 14]. The
combinationofsurfactantswithoilstoformmicroemulsions
oﬀers an advantage over a micellar or cosolvent system
in terms of the drug solubilization capacity for lipophilic
compounds, because of the extra solubilization provided
by the oil phase [15]. Also, because of the small droplet
diameter, microemulsions can be sterilized by ﬁltration [16].
The obvious beneﬁts of microemulsions as drug delivery
systems have led to the development of several systems for
intravenous administration of PTX in recent years. Recently,
two CrEL-free paclitaxel microemulsions were developed
for intravenous administration [17, 18]. In fact, most
PTXmicroemulsionsforintravenousadministrationcontain
CrEL.
Although PTX was ﬁrst discovered in the early 1960s, its
clinical development were delayed until the early 1980s, one
reason being its poor solubility. After much investigation,
CrEL, and dehydrated ethanol USP (1:1, v/v) was identiﬁed
as the most suitable option for the solvent system employed
in the commercial formulation of PTX, Taxol [19]. Until
now, although several reports have linked this solvent to
alterations in the pharmacokinetic proﬁle of PTX and the
production of side eﬀects, CrEL is still used as an excipient
for Taxol.
In the present study, a novel PTX microemulsion con-
taining a reduced amount of CrEL was prepared. The phar-
macokineticsandbiodistributionofthisPTXmicroemulsion
wereinvestigatedinrats.Theinvivoantitumoractivityofthe
PTX microemulsion was evaluated in tumor-bearing mice
and the safety of the PTX microemulsion was also evaluated.
2.MaterialandMethods
2.1. Materials. PTX and docetaxel were obtained from Mei-
Lian Co. Ltd. (Chongqing, China). Cremophor EL (CrEL)
was purchased from BASF Corporation of Germany (Local
Agent in Shanghai, China). Egg phosphatidylcholine (Lipoid
E 80) was obtained from Lipoid GmbH (Local Agent Shang-
hai Toshisun Enterprise Co., Ltd in Shanghai, China). PTX
injection was commercially available from a local hospital
in Beijing (Taxol, Bristol Myers Squibb Co., Princeton, NJ,
USA, for pharmacokinetic and biodistribution experiments;
PTX injection, Beijing Shiqiao Biological Pharmaceutical
Co., Ltd., Beijing, China, for antitumor and allergic reaction
experiments), and the PTX injection formulation contained
30mg PTX in 5mL 50% CrEL (v/v) and 50% dehydrated
ethanol (v/v). Medical products for premedication were also
commercially available from a local hospital in Beijing. All
other chemicals were of analytical grade or HPLC grade.
2.2. Animals and Cell Lines. Sprague-Dawley (SD) rats
weighing 200 ± 20g, New Zealand albino rabbits weigh-
ing 1.8–2.0kg and beagle dogs weighing 8–12kg were all
obtained from the Experimental Animal Center of Peking
University Health Science Center. Female BALB/C nude
mice weighing 18–22g (6–8 weeks) were purchased from
the Academy of Military Medical Sciences. All care and
handling of animals were performed in accordance with the
InstitutionalAuthorityforLaboratoryAnimalCareofPeking
University.
A human ovarian cancer cell line (OVCAR-3) and a
human nonsmall-cell lung cancer cell line (A 549) were
obtained from ATCC.
2.3. Preparation of PTX the Microemulsion. The PTX
microemulsion used in the experiment was prepared in our
laboratory with some modiﬁcation of the published method
[20]. In brief, to prepare PTX microemulsion concentrated
solution, PTX was dissolved in dehydrated alcohol and then
mixed with Lipoid E 80, CrEL and soybean oil. When
this concentrated solution was mixed with 5% glucose
infusion, it underwent self-emulsiﬁcation to form a PTX
microemulsion.
2.4. Physicochemical Characterization of the PTX Microemul-
sion. The volume of 5% glucose solution used for dilut-
ing the PTX concentration solution was 24mL (the ﬁnal
concentration of PTX in microemulsion was 1mg/mL). For
particle size analysis, this microemulsion was further diluted
with 5% glucose solution to a concentration of PTX about
0.03mg/mL. The particle size of the PTX microemulsion was
measured by photon correlation spectroscopy using Malvern
Zeta sizer nano-ZS instrument (Malvern, UK) at 25◦C. The
morphological examination of PTX microemulsions was
performed on a JEOL JEM-200CX instrument at an acceler-
ation voltage of 200kV by transmission electron microscope
(TEM). Brieﬂy, the TEM samples were prepared by dropping
one drop of PTX microemulsion (about 0.03mg/mL, PTX
concentrated solution was diluted with 5% glucose solution)
ontoa300-meshFormvar-coatedcoppergrid.Thegridswere
negativelystainedatroomtemperaturewithfreshlyprepared
andsterile-ﬁltered2%(w/v)uranylacetateaqueoussolution.
The grids were washed twice and air dried prior to imaging.
2.5. Pharmacokinetic Studies. Ten SD male rats were ran-
domly divided into two groups of ﬁve rats. All the animals
were fasted for 12h prior to the experiments. PTX injection
or microemulsion concentrated solution was diluted with
5% glucose injection at a concentration of 1mg/mL, respec-
tively. These PTX formulations were all injected into the tail
veinatasingledoseof5mg/kg.Bloodsamples(0.5mL)were
collected via the orbital venous plexus at 0, 0.17, 0.33, 0.67,
1, 1.5, 2, 3, 4, 6, and 8h after injection. After centrifugationJournal of Biomedicine and Biotechnology 3
at 3000g for 5min, the obtained plasma was stored at −20
◦C
until required for determination.
2.6. Biodistribution Studies. Twenty-four female rats were
randomly divided into two groups. PTX injection or
microemulsion concentrated solution was diluted with 5%
glucose injection at a concentration of 1mg/mL. These PTX
formulations were all given intravenously via the tail vein
at a dose of 5mg/kg. After drug administration, rats were
exsanguinated through the femoral artery at 0.167, 1, 4,
a n d8 h( t h r e er a t sf o re a c ht i m ep o i n t ) .T h eh e a r t ,l i v e r ,
spleen,lung,kidney,brain,andovarieswerecollected.Tissue
samples were blotted with paper towel, rinsed in saline,
blottedtoremoveexcessﬂuid,weighed,andstoredat −20
◦C.
2.7. In Vivo Antitumor Eﬃcacy. The female BALB/C nude
mice were inoculated subcutaneously in the right ﬂank
with 0.1mL of an OVCAR-3 cell suspension (4 × 106).
Administration was started at day 14 after inoculation when
the tumor size reached approximately 150mm3. On that day,
mice were randomly divided into a control group, a PTX
injection treatment group, and a PTX microemulsion treat-
ment group. Each group consisted of 6 tumor-bearing mice.
In another separate study, a solid tumor was established
following S.C. injection of 0.1mL of an A549 cell suspension
(5 × 106) into the right ﬂank of the mice. Treatments
were started when the tumor size reached approximately
150mm3, about 7 days after inoculation. On that day, mice
were randomly divided into a control group, a PTX injection
treatmentgroupandaPTXmicroemulsiontreatmentgroup.
Each group consisted of 6 tumor-bearing mice.
In the antitumor activity experiment, PTX injection or
microemulsion concentrated solution was diluted with 5%
glucose infusion to give a concentration of 1.5mg/mL. Each
group was treated with 5% glucose infusion, PTX injection
(15mg/kg, i.v., q4d4, every 4 days for four doses), or PTX
microemulsion (15mg/kg, i.v., q4d4, every 4 days for four
doses), respectively. Formulations were given intravenously
via the tail vein. Throughout the study, mice were weighed
andtumorsweremeasuredwithcaliperstwiceaweek.Tumor
volumes were calculated from the formula: V = length (cm)
× width (cm2) × 0.5236. Once an animal in any group died,
all the other animals in the experiment were sacriﬁced.
2.8. Intravenous Injection Safety Assessment. Hemolysis test:
rabbit blood was used to test the hemolytic eﬀect of the PTX
microemulsion. Brieﬂy, 10mL rabbit blood was obtained
from the arteria cruralis and the ﬁbrinogen was removed
by stirring with a glass rod. Then, 10 milliliter 5% glucose
infusion was added to the ﬁbrinogen-free blood sample and
supernatant was removed after centrifugation at 3000rpm
for 5min. The erythrocyte pellet at the bottom of centrifuge
tube was washed four times (centrifugation followed by re-
dispersion) with 5% glucose infusion. Finally, after repeated
washing and centrifugation, a suitable amount of 5% glucose
infusion was added to the erythrocyte pellet to give a 2%
erythrocytestandarddispersionwhichwasstoredat4◦C.The
PTX microemulsion concentrated solution was diluted with
5% glucose infusion to give a concentration of 1mg/mL, and
diﬀerent amounts of microemulsion in volumes of 0, 0.1,
0.2, 0.3, 0.4, and 0.5mL were added to six tubes each tube
containing 2.5mL 2% erythrocyte dispersion. Then, suitable
amounts of 5% glucose infusion were added to every tube
to obtain a ﬁnal volume of 5mL. A positive control was
prepared by addition of 2.5mL distilled water to 2.5mL 2%
erythrocyte dispersion instead of 5% glucose infusion. After
vortexing, the tubes were incubated at 37◦Ca n do b s e r v e d
microscopically from 15min to 4h.
Intravenous irritation assessment: one male and two
female rabbits weighing 1.8–2.0kg were used for this study.
PTX microemulsion concentrated solution was diluted with
5% glucose infusion to give a concentration of 1mg/mL.
Each rabbit (three animals) received a daily dose of 5mg/kg
PTX microemulsion into the vein at the edge of the left ear
at an injection rate of 1mL/min for 3 days. An equivalent
volume of 5% glucose infusion was injected into the right
ear-border vein of these three animals as a control. After
injection, the reaction at the injection site was recorded.
The rabbits were sacriﬁced by exsanguination 24h after the
last administration, and the ears were cut and ﬁxed in 10%
formaldehyde for histological examination. At sites 3cm
from the injection site to the proximal part, histological
sections were prepared for histopathological examination.
Allergic reaction: in the allergic reaction experiment,
PTX injection or microemulsion concentrated solution was
diluted with 5% glucose infusion to give a concentration of
0.6mg/mL. The beagle dogs were divided into ﬁve groups
(n = 6): a control group, a PTX injection treatment group,
a PTX microemulsion treatment group, a PTX injection
premedication treatment group, and a PTX microemul-
sion premedication treatment group. In the control group,
animals were given 5% glucose by infusion. In the PTX
formulationtreatmentgroups,thedilutedPTXformulations
were administered by infusion at a dosage of 165mg/m2
(8.25mg/kg). Infusion was initiated at a rate of 30mL/h for
10 minutes. If no allergic reaction was noted in the ﬁrst 10
minutes, the rate of infusion was increased to 60mL/h for
10 additional minutes, and if no reaction was noted, it was
increased again to 90mL/h for the rest of the infusion. The
total infusion time was between 3 and 6 hours. In the pre-
medication groups, the animals were initially premedicated
with prednisone (1mg/kg PO), diphenhydramine (4mg/kg
IM), cimetidine (4mg/kg IV), and dexamethasone Na Phos
(2mg/kg IV) according to a previous report [21], and then
they received the PTX formulations by infusion as the
PTX formulation treatment groups. The allergic reactions
exhibitedbytheanimalswereobservedandrankedaccording
to Table 1. After administration, animals were continuously
monitoredforatleast14daystofurtherevaluatetheirmental
state, food intake, and defecation. The body weights were
recorded on day 4, 8, and 12, and full blood cell counts were
carried out on day 4 and 8.
2.9. Measurement of PTX in Plasma, Blood, and Tissues. PTX
was measured in plasma and blood according to a previous
report [22]. Brieﬂy, an aliquot of 100μl plasma (or blood),
50μl docetaxel solution (10μg/mL, as an internal standard),4 Journal of Biomedicine and Biotechnology
Table 1: The severity of allergic reactions.
Grade 1/+ Grade 2/++ Grade 3/+++ Grade 4/++++
Mania Drowsiness Angioedema Life-threatening
Licking nose Rash/ﬂushing/urticaria Gatism Death
Transient ﬂushing or rash Mucous membrane hyperemia Vomiting
Head shaking Dyspnea
and 2.5mL acetonitrile were mixed using a vortex mixer for
30s. The mixture was centrifuged at 3000g for 10min, then
2.0mL supernatant was collected, and dried under a gentle
stream of nitrogen gas at 50◦Ci naw a t e rb a t h .T h er e s i d u e
was reconstituted using the mobile phase below, and assayed
by HPLC using a Waters system consisting of a 1525-pump,
anda2487-ultravioletdetector(WatersCo.,Inc.,Westerville,
OH, USA). The mobile phase consisted of methanol-water-
tetrahydrofuran (70:27.5:2.5, v/v/v) delivered at a ﬂow rate
of 1mL/min. Chromatographic separation was performed
on a Phenomenex ODS3 column (250 × 4.6mm, 5mm,
Torrance, CA, USA), and the detector wavelength was set at
230nm.ThepeakareasofPTX(Ap)anddocetaxel(Ad)were
recorded, and the concentration of PTX was calculated from
the ratio of Ap/Ad.
Tissue concentrations of PTX were also determined by
HPLC. Brieﬂy, tissue samples were homogenized in saline
andthehomogenate(0.7mL)wasmixedwith50μldoc etax el
solution (10μg/mL, as an internal standard), and 2.5mL
acetonitrile. After vortex mixing for 30s, the mixture was
centrifuged at 3000g for 10min, 2.0mL supernatant was
collected, and dried under a gentle stream of nitrogen gas
at 50◦C in a water bath. The residue was reconstituted using
themobile phaseandthendetermined byHPLCasdescribed
above for the measurement in plasma.
2.10. Statistical Analysis. Data are presented as the mean
± standard deviation (SD). One-way analysis of variance
(ANOVA) wasused to determine signiﬁcanceamong groups,
after which post-hoc tests with the Bonferroni correction
were used for comparison between individual groups. Statis-
tical signiﬁcance was established at P<. 05. Nonparametric
test (2 independence samples) was used to determine
signiﬁcance in Allergic reaction data. Statistical signiﬁcance
was established at P<. 05.
3. Results
3.1. Characterization of the PTX Microemulsion. The PTX
microemulsion concentrated solution was transparent and
slightly yellow in color. The concentration of PTX in the
microemuslion concentrated solution was 5mg/mL. The
average particle size of the PTX microemulsion after the
concentrated solution was diluted with 5% glucose infusion
was approximately 142.4 ± 1.2nm with a polydispersity
of 0.267 ± 0.07. The typical particle size and distribution
is shown in Figure 1(a). TEM was used to examine the
morphology of the PTX microemulsion (Figure 1(b)). The
TEM images revealed that the PTX microemulsion were
likely sphere in shape.
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Figure 1: Typical particle size and distribution of the PTX
microemulsion (a). Transmission electron micrograph of PTX
microemulsion ((b), Bar = 0.5μm).
3.2. Pharmacokinetics of the PTX Microemulsion after Intra-
venous Administration. The plasma concentration-time pro-
ﬁles of PTX after intravenous administration of the PTX
formulations (5mg/kg) were characterized in rats and
i l l u s t r a t e di nF i g u r e2. Data ﬁtting was conducted and
the result showed that the pharmacokinetic behavior of
the PTX microemulsion and PTX injection ﬁtted a two-
compartment model. As shown in Figure 2, the curve for
the PTX microemulsion group was similar to that of the
PTX injection group. The main pharmacokinetic parameters
o fP T Xa r es u m m a r i z e di nT a b l e2. As shown in Table 2,
the values of AUC0–8 in the PTX microemulsion group and
the PTX injection group were 3174.9 ± 592.4 and 3770.9 ±
796.2ng·h/mL, respectively. There was no signiﬁcant diﬀer-
enceinAUC0–8 betweenthesetwogroups.ThebioavailabilityJournal of Biomedicine and Biotechnology 5
Table 2: The main pharmacokinetic parameters of PTX after intravenous administration of the PTX injection or microemulsion at 5mg/kg
PTX in SD rats (mean ± S.D., n = 5).
Parameter Units PTX microemulsion PTX injection
A ng/mL 9245.8 ±3232.7 9315.2 ±2601.7
B ng/mL 1694.0 ±530.4 1611.0 ±651.5
α 1/h 5.934 ±2.40 6.219 ±1.104
β 1/h 0.689 ±0.216 0.837 ±0.139
t1/2α h0 .134 ±0.057 0.114 ±0.019
t1/2β h1 .074 ±0.279 0.846 ±0.130
t1/2 h0 .283 ±0.098 0.278 ±0.064
K12 1/h 2.393 ±1.197 2.431 ±0.537
K21 1/h 1.556 ±0.777 2.035 ±0.421
K10 1/h 2.674 ±0.826 2.590 ±0.523
AUC0–∞ h ng/mL 4141.7 ±787.6 4671.1 ±981.6
Vc mL/kg 1242.0 ±385.4 969.7 ±234.1
CL mL/h/kg 1239.2 ±212.4 1120.1 ±298.1
A and B: the hybrid parameters; α: distribution constant; β: elimination constant; t1/2α: half-time of phase I; t1/2β: half-time of phase II; K 21: rate constant
for drug leaving compartment 2 and passing into 1; K 12: rate constant for drug leaving compartment 1 and passing into 2; K 10: elimination constant from
the central compartment; AUC0–∞: area under the curve; Vc: apparent volume of distribution of the central compartment; CL: clearance from the two-
compartment model.
Table 3: The AUC0–8 values of PTX after intravenous administra-
tion of the PTX injection or microemulsion at 5mg/kg of PTX in
SD rats (mean ± S.D., n = 3).
PTX microemulsion PTX injection
Liver 54.84 ±9.10 59.62 ±8.16
Kidney 31.62 ±1.94 34.49 ±2.56
Lung 23.81 ±2.58 27.48 ±3.97
Spleen 23.13 ±2.05 25.95 ±1.95
Heart 13.10 ±1.05 13.94 ±1.36
Ovaries 15.20 16.58
of PTX in the microemulsion group compared with that in
the injection group was 84.2%. Meanwhile, there was no
signiﬁcant diﬀerence in the main parameters between the
PTX microemuslion group and the PTX injection group
(Table 2).
3.3. Tissue Distribution of the PTX Microemulsion after
Intravenous Administration. The tissue distribution proﬁles
of PTX in the PTX microemulsion group and the PTX
injection group were compared in rats. The concentration
of PTX in each tissue was determined by HPLC analysis. As
shown in Figure 3, PTX was widely and rapidly distributed
into most tissues following intravenous administration of
PTXformulations,andthehighestconcentrationofPTXwas
found in liver, followed by kidney and lung at 0.167h after
administration. However, after 8h, the drug concentration
rapidly decreased. The concentration of PTX in brain was
undeterminable.
The AUC values in tissues are listed in Table 3.T h e r e
was no signiﬁcant diﬀerence in the tissue distribution of
PTX between the PTX microemulsion group and the PTX
injection group.
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Figure 2: The plasma concentration-time proﬁles of PTX after
intravenous administration of PTX microemulsion or PTX injec-
tion at 5mg/kg PTX in SD rats (means ± S.D., n = 5).
3.4. In Vivo Antitumor Eﬃcacy. The in vivo antitumor activ-
ity of the PTX microemulsion was investigated in OVCAR-3
and A549 tumor-bearing mice. As shown in Figures 4(a) and
4(b), PTX microemulsion markedly inhibited the growth of
OVCAR-3 and A-549 tumors (P<. 01). A similar result was
observed in the PTX injection treatment group (P<. 01).
There was no signiﬁcant diﬀerence in the antitumor activity
between the microemulsion group and the injection group
(P>. 05).
In the OVCAR-3 tumor-bearing mice groups, the mean
tumorsizesatday33afterimplantationinthePTXinjection,
and the microemulsion group were 131 ± 112 and 63 ±
49mm3, respectively, compared with 690 ± 206mm3 in
the control group (P<. 01). The corresponding tumor6 Journal of Biomedicine and Biotechnology
Table 4: The rank of allergic reactions for each dog.
No. Control
group
Paclitaxel injection
treatment group
Paclitaxel microemulsion
treatment group
Paclitaxel injection
premedication treatment group
Paclitaxel microemulsion
premedication treatment group
1— + + + + + + + +
2— + + + + + + + +
3— + + + + + + + +
4— + + + + + + + +
5— + + + + + + + +
6 — +++ +++ +++ +
∗ ∗ ∗∗‡ ‡ † † § §
∗∗ P<. 01, Paclitaxel injection treatment group versus Paclitaxel microemulsion treatment group or Paclitaxel injection premedication treatment group.
‡‡ P>. 05, Paclitaxel microemulsion treatment group versus Paclitaxel injection premedication treatment group.
†† P<. 01, Paclitaxel microemulsion treatment group versus Paclitaxel microemulsion premedication treatment group.
§§ P<. 01, Paclitaxel injection premedication treatment group versus Paclitaxel microemulsion premedication treatment group.
growth inhibition in the PTX injection group and in the
PTX microemulsion treated group was 81.0% and 90.9%,
respectively. Similar results were also observed in the A
549 tumor-bearing mice groups, the mean tumor sizes
at day 32 after implantation in the PTX injection group
and the microemulsion group were 659 ± 228 and 528 ±
316mm3, respectively, compared with 1746 ± 520mm3 in
the control group (P<. 01). The corresponding tumor
growthinhibition inthePTXinjectiongroupandinthePTX
microemulsion group was 62.3% and 69.7%, respectively.
As shown in Figures 5(a) and 5(b), the average tumor
weight in the 5% glucose infusion, PTX injection, and
PTX microemulsion groups at day 33 after OVCAR-3 cell
implantation was 362 ± 105, 76 ± 94, and 40 ± 59mg,
respectively. The average tumor weight in the 5% glucose
infusion, PTX injection and PTX microemulsion groups at
day32 afterA549 cellimplantation was927±286, 353±142,
and 268 ±143mg, respectively.
Therewasnosigniﬁcantdiﬀerenceinbodyweightamong
the PTX microemulsion group, PTX injection group, and
control group (data not shown).
3.5. Injection Safety. Hemolysis test: complete hemolysis was
observed in the positive control tube at 15min, the solution
was red clearly diaphanous, and no erythrocytes survived at
the bottom of the tube. The erythrocytes were precipitated at
thebottom ofthe othersixtubes anddispersed aftershaking,
while the supernatant was achromatic and transparent over
the observation period of 4h. These results demonstrated
that the PTX microemulsion at a concentration of 1mg/mL
did not cause hemolysis and erythrocyte agglutination at
37◦C.
Intravenous irritation: after a 3-day administration of
pacltaxel microemulsion, 5% glucose infusion, no ery-
thema, and edema were observed at the injection sites.
The histopathologic examination of the rabbit ear-border
vein indicated that the vessel wall and endothelial cell
structures were unimpaired. Furthermore, no angiectasia
and thrombus formation was observed in the lumen of
the vein. There were no signiﬁcant pathological changes,
inﬂammatory cell inﬁltrate, hemorrhage epimorphosis, and
necrosis in the vessel walls and surrounding tissues. The
histopathologic examination results of the ears from rabbits
given the microemulsion were similar to those of the control
group. All the results demonstrated that PTX microemulsion
at a dose of 5mg/kg produced no irritation of the rabbit ear
veins.
Allergic reaction: the ranking of the allergic reactiona is
shown in Table 4. In the PTX injection group, the rank of
the allergic reaction was Grade 3/+++ in all animals (6/6).
Most animals in the PTX microemulsion group (5/6) and
the PTX injection premedication group (5/6) experienced
Grade 2/++. The rank of the allergic reaction in the PTX
microemulsionpremedicationgroupwasGrade1/+(6/6).In
the control group, the allergic reaction ranking was negative.
The main observed allergic reactions were transient ﬂushing
and rash, licking the nose, drowsiness, rash, angioedema,
mucous membrane hyperemia, vomiting, gatism, mania,
and dyspnea. The allergic reaction in paclitaxel injection
treatment group was signiﬁcantly serious than that in PTX
microemulsion treatment groups or paclitaxel injection
premedication treatment groups (P<. 01). Similar results
were also found in PTX microemulsion treatment group
versus PTX microemulsion premedication treatment group
(P<. 01) or paclitaxel injection premedication treatment
group versus PTX microemulsion premedication treatment
group (P<. 01). There were no signiﬁcant diﬀerences
observed in PTX microemulsion treatment group versus
paclitaxel injection premedication treatment group (P>
.05). After administration of PTX formulations, the body
weight decreased slightly compared with that of the control
group and but gradually returned to normal during the
observation phase. A similar phenomenon was also observed
for the white blood count and platelet count. There was
no signiﬁcant diﬀerence in toxic signs among the PTX
formulation groups.
4. Discussion
The commercially available PTX injection is a clear to
colorless formulation supplied in 5mL vials containing
PTX 6mg/mL, CrEL 527mg/mL, and dehydrated ethanol
396mg/mL. Therefore, the amounts of PTX, CrEL, and
dehydrated ethanol in a vial of PTX injection are 30mg,Journal of Biomedicine and Biotechnology 7
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Figure 3: The tissue distribution proﬁles of PTX in PTX microemulsion and PTX injection after intravenous administration of PTX
microemulsion or PTX injection at 5mg/kg PTX in SD rats (means ± S.D., n = 5).
2.6g and 2.4g, respectively. The amount of CrEL in the PTX
microemulsion concentrated solution was markedly reduced
comparedwiththatinthePTXinjection(from2.6gto0.8g).
When this microemulsion concentrated solution was diluted
with5%glucoseinfusion,theparticlesizeoftheformedPTX
microemulsion was about 150nm.
In the present study, we initially evaluated the pharma-
cokinetics and biodistribution of PTX in the microemulsion.
The curve of PTX in the microemulsion group was similar to
that in the PTX injection group (Figure 2) .T h eA U Cv a l u ei n
the PTX microemulsion group was slightly lower than that
in the PTX injection group. This was due to the CrEL which8 Journal of Biomedicine and Biotechnology
increased the concentration of PTX in plasma [23]. The
tissuedistributionproﬁlesofPTXinthePTXmicroemulsion
and the injection groups were compared in rats. There were
no signiﬁcant diﬀerences in PTX in the main tissues between
the microemulsion group and the injection group (Figure 3
and Table 3). These results indicate that the pharmacokinetic
and distribution properties of PTX in the microemulsion
were similar to those in the PTX injection. In addition, the
toxic eﬀect of PTX microemulsion to mice or rats will be
further investigated in future since the pharmacokinetics
behaviors of PTX may be inﬂuenced by the toxicity of its
vehicles.
It has been reported that PTX is commonly used to
treat ovarian, breast, and nonsmall cell lung cancers [24].
In the present study, we selected a human ovarian cancer
cell line (OVCAR-3) and a human nonsmall cell lung cancer
cell line (A 549) as animal tumor models. The in vivo
antitumorstudiesindicatedthattheantitumoreﬃcacyofthe
PTX microemulsion in OVCRA-3 and A 549 tumor-bearing
animals was similar to that of the PTX injection (Figures 4
and 5).
The resultsofinjection safetytest ofthe PTXmicroemul-
sion indicated that the PTX microemulsion did not cause
hemolysis, erythrocyte agglutination, and simulative reac-
tions, showing that it was safe to inject.
The allergic reaction studies showed that all animals in
the PTX formulation treatment groups experienced allergic
reactions, but to a varying degree. The allergic reactions
in the PTX microemulsion premedication group were not
as severe as those in the PTX injection premedication
group (P<. 01). Also, the allergic reactions in the PTX
microemulsion group were milder than those in the PTX
injection group (P<. 01), similar to those in the PTX
injection premedication group. It has been reported that
CrEL and its formulated micelles can cause allergic reactions
[25, 26] and dogs are known to be particularly sensitive
to agents that cause allergic reactions [25, 27]. Therefore,
in the present study, we chose beagle dogs as an animal
model to evaluating the allergic reactions caused by PTX
formulations. Due to the amount of CrEL necessary to
delivertherequireddosesofcyclosporineorteniposidebeing
much lower than that in the PTX injection, the reported side
eﬀects linked with CrEL are limited [28, 29]. Considering
the formulation of the present PTX microemulsion, the
amount of CrEL was markedly reduced compared with
that in the PTX injection (0.8g in microemulsion versus
2.6g in injection). Our allergic reaction results indicated
that the incidence and degree of allergic reactions in the
PTX microemulsion group, with or without premedication,
were signiﬁcantly lower than those in the PTX injection
group. Similar results were also observed in guinea pigs (data
not shown), indicating that the potential allergic reaction
induced by PTX microemulsion was signiﬁcantly decreased
compared with that in Taxol. Therefore, we suggest that
this PTX microemulsion containing less CrEL signiﬁcantly
reduces the allergic side eﬀects associated with CrEL.
Now, this PTX microemulsion concentration solution
has been approved for phase I trials by the China State Food
and Drug Administration (no. 2010L01157). The antitumor
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Figure 4: Tumor growth inhibition by PTX injection or PTX
microemulsion. BALB/C mice were inoculated s.c. with OVCAR-
3 cells (a) or A-549 cells (b) and treated with 5% glucose, PTX
injection or PTX microemulsion (15mg/kg, i.v., q4d4, every 4 days
for four doses), respectively. Tumor size was measured with calipers
twiceperweek.Resultsaregivenasmeans ±S.D.(n = 6). ∗∗P<. 01
versus 5% glucose infusion as control.
eﬃcacy and safety of the PTX microemulsion will now be
further evaluated in volunteers.
5. Conclusion
In summary, a novel PTX microemulsion delivery system
containing a reduced amount of CrEL was developed and
c h a r a c t e r i z e da sa ne ﬀective alternative to commercially
availablePTXinjection.ThePTXmicroemulsionhadsimilar
pharmacokinetic and antitumor eﬃcacy to the PTX injec-
tion, but signiﬁcantly reduced the allergic reactions caused
by CrEL. These results indicate that PTX microemulsion
overcomes the disadvantages of conventional PTX injection
and is one possible approach to avoid the limitations of
the current injection product and to produce a desirable
therapeutic eﬃcacy.Journal of Biomedicine and Biotechnology 9
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Figure 5: The mean tumor weight in the 5% glucose infusion, PTX
injection and PTX microemulsion groups at day 33 after OVCAR-
3 cell implantation (a) or A-549 cells (b) at day 32 after A 549 cell
implantation. Results are given as means ± S.D. (n = 6). ∗∗P<. 01
versus 5% glucose infusion as control.
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